Omeros Corp (OMER) 20.63 $OMER
Investors' Radars Failed to Catch Omeros Corporation (OMER), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:42AM CST
If you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Omeros Corporation (OMER)
OMER: 20.63 (+0.13)
Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Tue Feb 03, 4:34PM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price of $0.01 per share and will expire on February 3, 2022. Gross proceeds from the offering were approximately $84.0 million, including approximately $15.0 million from the sale of the pre-funded warrants. The closing also included the sale of 449,325 shares of common stock sold pursuant to the option allowing the underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $79.1 million.
OMER: 20.63 (+0.13)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ARLP: 39.29 (+1.84), HTBX: 5.83 (+0.22), EVOK: 5.41 (-0.10), ADXS: 7.18 (+0.06), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SONS: 17.69 (-0.01), SSYS: 67.16 (-0.34), ICPT: 209.12 (+7.12), VBLT: 14.11 (+0.24), LMNX: 15.45 (+0.02), OMER: 20.63 (+0.13)
Why Omeros Corporation Shares Plunged Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 3:49PM CST
What: In the wake of announcing a $75 million public offering last week -- expected to close by Feb. 3 -- shares in Omeros Corporation sank by as much as 10% today, closing down 7.6%. So What: Omeros is a biotechnology company that is...
OMER: 20.63 (+0.13)
Omeros expects USD75m gross proceeds from public offering of common stock and pre-funded warrants
M2 - Fri Jan 30, 11:13PM CST
Biopharmaceutical company Omeros Corporation (NasdaqGM:OMER) said on Thursday that it has priced its public offering of 2,995,506 shares of its common stock at USD20.03 per share plus pre-funded warrants to purchase up to 749,250 shares of its common stock at USD20.02 per warrant.
OMER: 20.63 (+0.13)
Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Thu Jan 29, 7:32AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. The pre-funded warrants have a term of seven years and an exercise price of $0.01 per share. Total gross proceeds, including the approximately $15 million to be received on the pre-funded warrants, will be approximately $75 million. The net proceeds from this offering, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $70.6 million. Omeros has also granted the underwriters a 30-day option to purchase up to an additional 449,325 shares of common stock to cover overallotments, if any, which would result in additional gross proceeds of approximately $9 million if exercised in full. The offering is expected to close on or about February 3, 2015, subject to customary closing conditions.
OMER: 20.63 (+0.13)
Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Wed Jan 28, 3:01PM CST
Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering. The pre-funded warrants shall be offered at the same price per share as the common stock, less the $0.01 per share exercise price of each pre-funded warrant. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any.
OMER: 20.63 (+0.13)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Osteoporosis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/smnrjh/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abiogen Pharma S.p.A. - Alethia Biotherapeutics - Biodel - Bone Medical - Calzada - Dong Wha Pharma - Dongkook Pharmaceutical - ElexoPharm GmbH - F. Hoffmann-La Roche - Galapagos NV - Glide Pharmaceutical Technologies - IMMD - Immunovo BV - Inbiopro Solutions Pvt. - Kaken Pharmaceutical - Kedem Pharmaceuticals - Lead Discovery Center GmbH - Lupin - Medivir AB - Merck & Co. - Merrion Pharmaceuticals Plc - NeoStem - Novartis AG - Omeros Corporation - Pfizer - PhytoHealth Corporation - Radius Health - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma - TSRL For more information visit http://www.researchandmarkets.com/research/sm...teoporosis
RDUS: 50.37 (+0.63), MRK: 58.81 (-0.07), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 20.63 (+0.13)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 229.49 (+1.87), EYEG: (), OHRP: 7.38 (-0.30), REGN: 402.40 (+0.66), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
PR Newswire - Wed Nov 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS.
OMER: 20.63 (+0.13)
Investors' Radars Failed to Catch Omeros Corporation (OMER), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:42AM CST
If you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Omeros Corporation (OMER)
OMER: 20.63 (+0.13)
Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Tue Feb 03, 4:34PM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price of $0.01 per share and will expire on February 3, 2022. Gross proceeds from the offering were approximately $84.0 million, including approximately $15.0 million from the sale of the pre-funded warrants. The closing also included the sale of 449,325 shares of common stock sold pursuant to the option allowing the underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $79.1 million.
OMER: 20.63 (+0.13)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ARLP: 39.29 (+1.84), HTBX: 5.83 (+0.22), EVOK: 5.41 (-0.10), ADXS: 7.18 (+0.06), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SONS: 17.69 (-0.01), SSYS: 67.16 (-0.34), ICPT: 209.12 (+7.12), VBLT: 14.11 (+0.24), LMNX: 15.45 (+0.02), OMER: 20.63 (+0.13)
Why Omeros Corporation Shares Plunged Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 3:49PM CST
What: In the wake of announcing a $75 million public offering last week -- expected to close by Feb. 3 -- shares in Omeros Corporation sank by as much as 10% today, closing down 7.6%. So What: Omeros is a biotechnology company that is...
OMER: 20.63 (+0.13)
Omeros expects USD75m gross proceeds from public offering of common stock and pre-funded warrants
M2 - Fri Jan 30, 11:13PM CST
Biopharmaceutical company Omeros Corporation (NasdaqGM:OMER) said on Thursday that it has priced its public offering of 2,995,506 shares of its common stock at USD20.03 per share plus pre-funded warrants to purchase up to 749,250 shares of its common stock at USD20.02 per warrant.
OMER: 20.63 (+0.13)
Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Thu Jan 29, 7:32AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. The pre-funded warrants have a term of seven years and an exercise price of $0.01 per share. Total gross proceeds, including the approximately $15 million to be received on the pre-funded warrants, will be approximately $75 million. The net proceeds from this offering, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $70.6 million. Omeros has also granted the underwriters a 30-day option to purchase up to an additional 449,325 shares of common stock to cover overallotments, if any, which would result in additional gross proceeds of approximately $9 million if exercised in full. The offering is expected to close on or about February 3, 2015, subject to customary closing conditions.
OMER: 20.63 (+0.13)
Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
PR Newswire - Wed Jan 28, 3:01PM CST
Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering. The pre-funded warrants shall be offered at the same price per share as the common stock, less the $0.01 per share exercise price of each pre-funded warrant. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any.
OMER: 20.63 (+0.13)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Osteoporosis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/smnrjh/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abiogen Pharma S.p.A. - Alethia Biotherapeutics - Biodel - Bone Medical - Calzada - Dong Wha Pharma - Dongkook Pharmaceutical - ElexoPharm GmbH - F. Hoffmann-La Roche - Galapagos NV - Glide Pharmaceutical Technologies - IMMD - Immunovo BV - Inbiopro Solutions Pvt. - Kaken Pharmaceutical - Kedem Pharmaceuticals - Lead Discovery Center GmbH - Lupin - Medivir AB - Merck & Co. - Merrion Pharmaceuticals Plc - NeoStem - Novartis AG - Omeros Corporation - Pfizer - PhytoHealth Corporation - Radius Health - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma - TSRL For more information visit http://www.researchandmarkets.com/research/sm...teoporosis
RDUS: 50.37 (+0.63), MRK: 58.81 (-0.07), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 20.63 (+0.13)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 37.22 (+0.27), TNXP: 5.78 (-0.02), MRNS: 10.94 (-0.06), CPRX: 3.36 (-0.10), VNDA: 12.37 (unch), ITCI: 24.53 (+2.45), OMER: 20.63 (+0.13)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 229.49 (+1.87), EYEG: (), OHRP: 7.38 (-0.30), REGN: 402.40 (+0.66), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
PR Newswire - Wed Nov 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS.
OMER: 20.63 (+0.13)
